1. The three preferred first-line oral agents for chronic hepatitis B — tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir — belong to a class called nucleos(t)ide analogues (drugs that mimic the natural building blocks of DNA). What is the shared mechanism by which these drugs suppress hepatitis B virus (HBV) replication?
A) They neutralize the hepatitis B surface antigen on the viral envelope, preventing the virus from attaching to hepatocytes
B) They inhibit HBV reverse transcriptase, the enzyme that copies viral RNA into viral DNA, terminating DNA chain elongation
C) They stimulate host interferon-stimulated genes that degrade intracellular viral particles
D) They block the host enzyme that adds a polyadenine tail to viral messenger RNA, preventing protein translation
E) They covalently bind and eliminate the covalently closed circular DNA (cccDNA) reservoir within the hepatocyte nucleus
ANSWER: B
Rationale:
Tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir are all nucleos(t)ide analogues that inhibit HBV reverse transcriptase, the enzyme responsible for converting pregenomic viral RNA into HBV DNA. After incorporation into the growing viral DNA strand, these analogues act as chain terminators, halting elongation and thereby suppressing viral replication for as long as therapy continues. Understanding this shared mechanism explains why the class is potent at viral suppression yet does not cure the infection.
Option A: Option A is incorrect because these agents do not act on the surface antigen or block viral attachment; entry inhibition is the mechanism of bulevirtide in hepatitis D, not of the HBV nucleos(t)ide analogues.
Option C: Option C is incorrect because interferon-stimulated gene induction describes the mechanism of pegylated interferon-alpha, an entirely different therapeutic approach, not the nucleos(t)ide analogues.
Option D: Option D is incorrect because it describes a fabricated mechanism; these drugs do not target messenger RNA polyadenylation.
Option E: Option E is incorrect because nucleos(t)ide analogues notably do NOT eliminate the cccDNA reservoir in hepatocyte nuclei, which is precisely why treatment is generally lifelong in the absence of surface antigen loss.
2. A patient with chronic hepatitis B achieves undetectable HBV DNA after one year on entecavir. The patient asks how long treatment must continue. Why is nucleos(t)ide analogue therapy for chronic hepatitis B generally considered lifelong for most patients?
A) The virus rapidly develops resistance to entecavir within two years, requiring indefinite dose escalation to maintain suppression
B) These drugs accumulate in hepatocytes over time and must be continued to prevent a toxic withdrawal reaction
C) The drugs lose potency against circulating virus after the first year, so continued dosing compensates for declining efficacy
D) The drugs suppress replication but do not eliminate the covalently closed circular DNA (cccDNA) template in hepatocyte nuclei, so virus rebounds when therapy stops
E) Hepatitis B surface antigen levels rise during treatment, requiring ongoing therapy to keep the antigen suppressed
ANSWER: D
Rationale:
Nucleos(t)ide analogues potently suppress active viral replication, but they do not clear the cccDNA — the stable, transcriptionally active viral DNA template that persists in the nucleus of infected hepatocytes. Because this reservoir remains intact, stopping therapy typically allows viral replication to rebound, which is why treatment is generally lifelong for most patients in the absence of hepatitis B surface antigen loss. This concept explains why current therapy controls rather than cures the infection.
Option A: Option A is incorrect because entecavir has an excellent resistance profile in treatment-naive patients (resistance under about 1.2% at five years), so resistance is not the reason for indefinite therapy.
Option B: Option B is incorrect because there is no toxic accumulation or withdrawal reaction; the concern with stopping is viral rebound and hepatitis flare, not drug toxicity.
Option C: Option C is incorrect because the drugs do not lose potency over time against circulating virus.
Option E: Option E is incorrect because surface antigen levels do not rise during effective therapy; loss of surface antigen is in fact the aspirational endpoint that would permit stopping treatment.
3. Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are both prodrugs of tenofovir with equivalent antiviral efficacy against hepatitis B. For a patient with reduced kidney function or low bone mineral density, which agent is preferred and why?
A) TAF is preferred because it delivers tenofovir to hepatocytes more efficiently at a much lower dose, producing less systemic tenofovir exposure and a better renal and bone safety profile
B) TDF is preferred because it is cleared entirely by the liver and therefore spares the kidney from any drug exposure
C) TAF is preferred because it is not actually a tenofovir prodrug and has no overlap with TDF in mechanism or toxicity
D) TDF is preferred because its higher systemic tenofovir levels protect bone mineral density through a direct osteoblast-stimulating effect
E) The two agents are interchangeable in renal impairment because neither produces meaningful systemic tenofovir exposure
ANSWER: A
Rationale:
TAF delivers tenofovir to hepatocytes far more efficiently than TDF, achieving equivalent antiviral effect at roughly one-tenth the dose (about 25 mg versus 300 mg daily) with substantially lower systemic tenofovir exposure. Because the dose-dependent toxicities of tenofovir — proximal renal tubular dysfunction and reduced bone mineral density — track with systemic exposure, TAF carries a meaningfully better renal and bone safety profile and is preferred in patients with renal impairment or low bone density.
Option B: Option B is incorrect because TDF is not cleared entirely by the liver; in fact it produces higher systemic tenofovir exposure and carries the greater renal risk.
Option C: Option C is incorrect because TAF is indeed a tenofovir prodrug; both agents deliver the same active moiety, and the difference is in distribution and exposure, not mechanism.
Option D: Option D inverts the relationship: higher systemic tenofovir exposure with TDF is associated with reduced, not improved, bone mineral density.
Option E: Option E is incorrect because the agents are not interchangeable in renal impairment; their differing systemic exposure is precisely what drives the preference for TAF in that setting.
4. Entecavir has an excellent resistance barrier in treatment-naive patients with chronic hepatitis B. However, it has one important limitation. In which patient should entecavir NOT be used as monotherapy, and why?
A) A patient with normal renal function, because entecavir requires impaired clearance to reach therapeutic levels
B) A patient who is hepatitis B e antigen positive, because entecavir is only active against e antigen negative disease
C) A patient previously treated with lamivudine, because lamivudine resistance mutations greatly reduce entecavir efficacy and promote entecavir resistance
D) A patient coinfected with hepatitis C, because entecavir accelerates hepatitis C replication
E) A patient over age 65, because entecavir is contraindicated in older adults due to neurotoxicity
ANSWER: C
Rationale:
Entecavir's resistance barrier is excellent in treatment-naive patients, but the lamivudine resistance mutations (M204V and M204I) substantially reduce entecavir efficacy. In lamivudine-experienced patients, entecavir resistance emerges in roughly half of patients over five years, so entecavir should not be used as rescue monotherapy for lamivudine-resistant HBV; tenofovir (TDF or TAF) is the appropriate choice in that setting. This cross-resistance concept is essential to selecting the right rescue agent.
Option A: Option A is incorrect because entecavir does not depend on impaired clearance; it is active in patients with normal renal function and is in fact dose-reduced in renal impairment.
Option B: Option B is incorrect because entecavir is effective in both e antigen positive and e antigen negative disease.
Option D: Option D is incorrect because entecavir does not accelerate hepatitis C replication; it is an HBV-directed agent without that interaction.
Option E: Option E is incorrect because entecavir is not contraindicated in older adults and does not cause the described neurotoxicity.
5. A clinician is monitoring a patient on nucleos(t)ide analogue therapy for chronic hepatitis B. Which laboratory result represents the principal on-treatment endpoint that defines successful viral suppression?
A) Normalization of serum bilirubin to below 1.0 mg/dL
B) A rise in hepatitis B surface antigen titer indicating immune activation
C) Detectable hepatitis B e antigen confirming ongoing replication is controlled
D) A serum tenofovir trough concentration within a defined therapeutic range
E) Undetectable HBV DNA on a sensitive polymerase chain reaction assay, typically below 20 IU/mL
ANSWER: E
Rationale:
The principal treatment endpoint for nucleos(t)ide analogue therapy is suppression of HBV DNA to undetectable levels on a sensitive polymerase chain reaction assay, generally defined as below about 20 IU/mL. This directly reflects control of viral replication, which halts necroinflammation and reduces fibrosis progression and cancer risk. Secondary endpoints include normalization of alanine aminotransferase and e antigen seroconversion, with surface antigen loss being the aspirational functional cure.
Option A: Option A is incorrect because bilirubin normalization is not the defining endpoint of viral suppression; HBV DNA is the direct virologic measure.
Option B: Option B is incorrect and inverted: a RISE in surface antigen is not a goal — loss of surface antigen is the aspirational endpoint, and a rising titer would not signal success.
Option C: Option C is incorrect because detectable e antigen indicates ongoing active replication rather than control; the favorable change is e antigen seroconversion (its loss with development of anti-HBe).
Option D: Option D is incorrect because routine therapeutic drug monitoring of tenofovir trough levels is not used to define treatment success; the virologic measure (HBV DNA) is the endpoint.
6. Pegylated interferon-alpha is an alternative to nucleos(t)ide analogues for selected patients with chronic hepatitis B. Compared with nucleos(t)ide analogue therapy, what is the principal advantage of pegylated interferon-alpha?
A) It is taken as a once-daily oral tablet, improving adherence over injectable regimens
B) It offers a defined, finite treatment duration (typically 48 weeks) with the possibility of a durable off-therapy response, rather than indefinite therapy
C) It is safe to use in decompensated cirrhosis, unlike the nucleos(t)ide analogues
D) It eliminates the cccDNA reservoir, producing a reliable virologic cure in most patients
E) It has essentially no adverse effects, making it the preferred agent for frail patients
ANSWER: B
Rationale:
The principal advantage of pegylated interferon-alpha over nucleos(t)ide analogues is its finite treatment course — typically 48 weeks — with the possibility of a durable off-therapy response, in contrast to the generally indefinite duration of nucleos(t)ide analogue therapy. It also offers higher rates of e antigen seroconversion and surface antigen decline and carries no risk of drug resistance.
Option A: Option A is incorrect because pegylated interferon is given by subcutaneous injection (180 mcg weekly), not as an oral tablet; the nucleos(t)ide analogues are the oral agents.
Option C: Option C is incorrect because it inverts the truth: pegylated interferon is contraindicated in decompensated cirrhosis because it can precipitate hepatic decompensation, whereas it is the nucleos(t)ide analogues that are used in that setting.
Option D: Option D is incorrect because pegylated interferon does not eliminate cccDNA or reliably cure infection; functional cure remains uncommon.
Option E: Option E is incorrect because pegylated interferon has a substantial adverse-effect burden — flu-like symptoms, fatigue, marrow suppression, depression, and thyroid dysfunction — making it a poor choice for frail patients.
7. A patient with resolved hepatitis B (surface antigen negative, core antibody positive) is scheduled to begin rituximab, an anti-CD20 monoclonal antibody, for lymphoma. Why is this patient at particular risk, and what is the underlying principle?
A) Immunosuppressive therapy can disrupt immune control of HBV and trigger reactivation — an abrupt rise in HBV DNA that may cause acute liver failure — so screening and prophylaxis are required
B) Rituximab directly damages hepatocytes through a toxic metabolite, an effect unrelated to the patient's prior hepatitis B
C) Anti-CD20 therapy reliably cures hepatitis B by depleting the infected B cells that harbor the virus
D) The patient is at no meaningful risk because surface antigen negativity indicates the virus has been completely eradicated from the body
E) Reactivation occurs only in patients who are surface antigen positive; core antibody positive patients require no monitoring or prophylaxis
ANSWER: A
Rationale:
HBV reactivation is an abrupt increase in HBV DNA in a patient with resolved or inactive infection, occurring when immunosuppressive therapy disrupts the immune surveillance that normally controls the virus. Anti-CD20 agents such as rituximab are a high-risk trigger, and reactivation can progress to acute liver failure and death. This is why patients are screened for surface antigen and core antibody before immunosuppression, with prophylactic nucleos(t)ide analogue therapy (TAF or entecavir preferred) for those at risk.
Option B: Option B is incorrect because the risk arises from loss of immune control of latent virus, not from direct hepatotoxic metabolite injury by rituximab.
Option C: Option C is incorrect because anti-CD20 therapy does not cure hepatitis B; by suppressing immunity it increases reactivation risk.
Option D: Option D is incorrect because surface antigen negativity does not mean the virus is fully eradicated — core antibody positivity reflects prior infection with persistent cccDNA that can reactivate.
Option E: Option E is incorrect because core antibody positive, surface antigen negative patients are not risk-free; they require at minimum close monitoring and prophylaxis for high-risk regimens such as rituximab.
8. The treatment of chronic hepatitis C was transformed by direct-acting antivirals (DAAs) — oral drugs that target specific viral proteins. DAAs are grouped into classes based on which viral protein they inhibit. Which three nonstructural viral proteins are the targets of the three main DAA classes?
A) The surface glycoprotein, the matrix protein, and the nucleocapsid protein
B) Reverse transcriptase, integrase, and the surface antigen
C) The host CYP3A4 enzyme, P-glycoprotein, and the sodium-taurocholate cotransporting polypeptide
D) The NS5B RNA-dependent RNA polymerase, the NS5A replication-complex protein, and the NS3/4A serine protease
E) DNA gyrase, topoisomerase IV, and dihydrofolate reductase
ANSWER: D
Rationale:
The three main DAA classes target three nonstructural (NS) hepatitis C proteins: the NS5B RNA-dependent RNA polymerase (inhibited by sofosbuvir), the NS5A protein that scaffolds the replication complex (inhibited by the "-asvir" agents such as velpatasvir and pibrentasvir), and the NS3/4A serine protease that processes the viral polyprotein (inhibited by the "-previr" agents such as glecaprevir). Recognizing these targets explains how combination regimens attack the virus at multiple steps.
Option A: Option A is incorrect because the surface, matrix, and nucleocapsid proteins are not the DAA targets; the DAA classes are defined by the nonstructural proteins.
Option B: Option B is incorrect because reverse transcriptase, integrase, and surface antigen are relevant to HBV or HIV, not the hepatitis C DAA targets.
Option C: Option C is incorrect because CYP3A4, P-glycoprotein, and the sodium-taurocholate cotransporting polypeptide are host factors relevant to drug interactions or to bulevirtide in hepatitis D, not the DAA viral targets.
Option E: Option E is incorrect because DNA gyrase, topoisomerase IV, and dihydrofolate reductase are antibacterial drug targets unrelated to antiviral DAA therapy.
9. After completing a course of direct-acting antiviral therapy for hepatitis C, a patient is told they have achieved "SVR12." What does sustained virologic response at 12 weeks (SVR12) signify?
A) The patient's viral load has fallen by at least 12 percent from baseline, indicating partial treatment response
B) The patient must continue therapy for an additional 12 weeks to consolidate the response
C) Undetectable hepatitis C RNA 12 weeks after completing treatment, which is accepted as virologic cure in the vast majority of patients
D) The patient has developed protective immunity that prevents any future hepatitis C reinfection
E) The hepatitis C virus has become dormant and is expected to relapse within 12 months in most patients
ANSWER: C
Rationale:
SVR12 means undetectable hepatitis C RNA measured 12 weeks after completing treatment, and it is the accepted definition of virologic cure: patients who reach SVR12 do not relapse virologically in the vast majority of cases. Long-term follow-up shows sustained RNA negativity, regression of fibrosis, and reduced liver-related and all-cause mortality.
Option A: Option A is incorrect because SVR12 is not a percentage reduction in viral load; it is undetectable RNA at a defined time point after therapy ends.
Option B: Option B is incorrect because SVR12 is assessed AFTER treatment is finished, not a signal to extend therapy.
Option D: Option D is incorrect because cure does not confer protective immunity — patients can be reinfected on re-exposure, so SVR12 is not immunity.
Option E: Option E is incorrect because it inverts the meaning: SVR12 indicates durable cure, not impending relapse, and relapse after a true SVR12 is rare.
10. Sofosbuvir is a backbone component of many hepatitis C regimens. It is a uridine nucleotide analogue prodrug. By what mechanism does sofosbuvir suppress hepatitis C, and what clinically useful property follows from that mechanism?
A) It inhibits the NS3/4A protease, and as a result it has the most drug interactions of any DAA class
B) It blocks the NS5A scaffold protein, and therefore must never be combined with other DAA classes
C) It inhibits host CYP3A4, and therefore boosts the levels of co-administered antivirals
D) It blocks viral entry at the sodium-taurocholate cotransporting polypeptide receptor, sparing already-infected cells
E) After conversion to its active triphosphate, it acts as a chain terminator at the NS5B polymerase, giving it an exceptionally high barrier to clinical resistance
ANSWER: E
Rationale:
Sofosbuvir is a nucleotide analogue prodrug that, after intracellular conversion to its active triphosphate, incorporates into nascent hepatitis C RNA and terminates chain elongation at the NS5B RNA-dependent RNA polymerase. Because the resistance substitution (S282T) carries a high fitness cost, sofosbuvir has an exceptionally high barrier to clinical resistance, making it one of the most durable DAA components.
Option A: Option A is incorrect because sofosbuvir is an NS5B inhibitor, not an NS3/4A protease inhibitor; it is the protease inhibitors that carry the larger drug-interaction burden.
Option B: Option B is incorrect because sofosbuvir is an NS5B inhibitor, not an NS5A inhibitor; and it is in fact routinely combined with other classes such as NS5A inhibitors.
Option C: Option C is incorrect because sofosbuvir does not inhibit CYP3A4 or act as a pharmacokinetic booster.
Option D: Option D is incorrect because entry inhibition at the sodium-taurocholate cotransporting polypeptide describes bulevirtide in hepatitis D, not sofosbuvir.
11. NS5A inhibitors (the "-asvir" agents such as velpatasvir and pibrentasvir) are potent across hepatitis C genotypes. Yet they are always given in combination with at least one drug from another class. What property explains this rule?
A) NS5A inhibitors are inactive against genotype 3 and rely on a partner drug to cover that genotype
B) Used alone, NS5A inhibitors have a relatively low barrier to resistance, so a partner agent from another class is required to prevent resistant breakthrough
C) NS5A inhibitors are prodrugs that must be activated by a co-administered protease inhibitor
D) NS5A inhibitors have no antiviral activity of their own and serve only to boost the levels of the partner drug
E) NS5A inhibitors are too toxic at monotherapy doses, so combination allows a lower, safer dose of each
ANSWER: B
Rationale:
NS5A inhibitors are highly potent and broadly active across genotypes, but used alone they have a relatively low barrier to resistance compared with the NS5B nucleotide inhibitor sofosbuvir. Combining them with an agent from another class (an NS5B or NS3/4A inhibitor) suppresses the emergence of resistant virus, which is why they are never used as monotherapy.
Option A: Option A is incorrect because pibrentasvir in particular has strong pan-genotypic activity, including against the historically difficult genotype 3; lack of genotype 3 coverage is not the reason for combination.
Option C: Option C is incorrect because NS5A inhibitors are not prodrugs requiring activation by a protease inhibitor.
Option D: Option D is incorrect because NS5A inhibitors have genuine, potent antiviral activity; they are not mere pharmacokinetic boosters.
Option E: Option E is incorrect because the rationale for combination is preventing resistance, not avoiding monotherapy toxicity through dose reduction.
12. A patient with hepatitis C and advanced chronic kidney disease, including those on dialysis, needs treatment. Among the pan-genotypic regimens, glecaprevir/pibrentasvir has a particular advantage in this setting. What is it?
A) Glecaprevir/pibrentasvir does not require dose adjustment in renal impairment, making it a preferred pan-genotypic option in advanced kidney disease and dialysis
B) Glecaprevir/pibrentasvir is cleared exclusively by the kidney, so impaired renal function raises its levels and improves efficacy
C) Glecaprevir/pibrentasvir contains sofosbuvir, whose renal metabolite is safely dialyzed off between treatments
D) Glecaprevir/pibrentasvir is the only regimen safe to combine with amiodarone in dialysis patients
E) Glecaprevir/pibrentasvir reverses chronic kidney disease as a direct pharmacologic effect during the treatment course
ANSWER: A
Rationale:
Glecaprevir/pibrentasvir combines an NS3/4A inhibitor with an NS5A inhibitor and contains no sofosbuvir component. Because it does not depend on renal elimination in the way sofosbuvir-containing regimens do, it does not require dose adjustment in renal impairment and is a preferred pan-genotypic choice for patients with chronic kidney disease, including those on dialysis.
Option B: Option B is incorrect because the regimen is not renally cleared in a way that raises levels usefully; the advantage is that it can be given at standard dose, not that renal failure boosts efficacy.
Option C: Option C is incorrect because glecaprevir/pibrentasvir does NOT contain sofosbuvir; that is precisely why it avoids the sofosbuvir metabolite accumulation seen in severe renal impairment.
Option D: Option D is incorrect because the dangerous amiodarone interaction is specifically with sofosbuvir-containing regimens; glecaprevir/pibrentasvir is sofosbuvir-free, but this option misstates the issue as a unique amiodarone-compatibility claim.
Option E: Option E is incorrect because no DAA reverses chronic kidney disease; the benefit is pharmacokinetic suitability, not renal recovery.
13. Before starting a sofosbuvir-containing hepatitis C regimen, the clinician reviews the patient's medication list. Which co-medication is associated with a risk of serious, potentially fatal symptomatic bradycardia when combined with a sofosbuvir-containing regimen?
A) Metformin
B) Levothyroxine
C) Omeprazole
D) Amiodarone
E) Acetaminophen
ANSWER: D
Rationale:
Amiodarone combined with any sofosbuvir-containing regimen carries a risk of serious symptomatic bradycardia, including fatal cases; the combination is contraindicated unless no alternative exists and continuous cardiac monitoring is available. Screening the medication list for amiodarone is therefore an essential pre-treatment step.
Option A: Option A is incorrect because metformin does not cause this bradycardia interaction with sofosbuvir.
Option B: Option B is incorrect because levothyroxine has no such interaction with sofosbuvir-containing regimens.
Option C: Option C is incorrect because omeprazole, while relevant to acid-dependent absorption of some DAAs, is not the agent associated with the fatal bradycardia warning.
Option E: Option E is incorrect because acetaminophen does not produce the sofosbuvir-amiodarone bradycardia risk; acetaminophen's relevance in this chapter is hepatotoxicity in overdose, a separate issue.
14. A patient about to start a protease inhibitor-containing DAA regimen (such as glecaprevir/pibrentasvir) is taking rifampin, a strong inducer of CYP3A4 and P-glycoprotein. Why is this combination an absolute contraindication?
A) Rifampin inhibits the metabolism of the DAA, raising its levels to toxic concentrations
B) Rifampin and the DAA both prolong the QT interval, producing additive arrhythmia risk
C) Rifampin induces the enzymes and transporters that clear the DAA, lowering DAA plasma levels to subtherapeutic concentrations and risking treatment failure
D) Rifampin chemically inactivates the DAA within the gastrointestinal lumen before absorption
E) Rifampin displaces the DAA from plasma protein binding, causing an immediate hypersensitivity reaction
ANSWER: C
Rationale:
Strong CYP3A4 and P-glycoprotein inducers such as rifampin increase the clearance of DAAs, driving plasma concentrations to subtherapeutic levels and risking virologic failure and resistance. This is why such inducers are absolute contraindications with protease inhibitor-containing regimens, and a drug-interaction check is mandatory before initiating any DAA.
Option A: Option A is incorrect because it inverts the mechanism: rifampin is an inducer, not an inhibitor, so it lowers DAA levels rather than raising them to toxic concentrations.
Option B: Option B is incorrect because the problem is loss of efficacy from induction, not additive QT prolongation.
Option D: Option D is incorrect because rifampin does not chemically inactivate the DAA in the gut lumen; the mechanism is enzyme and transporter induction.
Option E: Option E is incorrect because protein-binding displacement causing hypersensitivity is not the mechanism; the clinically important effect is induced metabolism lowering drug exposure.
15. Hepatitis D virus (HDV) is a defective RNA virus. A patient can only be infected with HDV under one specific condition. What is the obligate requirement for HDV infection, and why?
A) HDV requires prior hepatitis C infection because it borrows the hepatitis C replication machinery
B) HDV requires hepatitis B virus surface antigen for its assembly and transmission, so infection occurs only in patients with concurrent or prior hepatitis B
C) HDV requires immunosuppression to establish infection and cannot infect immunocompetent patients
D) HDV requires a functioning host CYP2E1 enzyme to bioactivate its capsid protein
E) HDV can infect any patient independently and has no dependence on another virus
ANSWER: B
Rationale:
HDV is a defective virus that depends on hepatitis B virus surface antigen for its assembly and transmission. As a result, HDV infection is only possible in patients who have concurrent or prior hepatitis B infection — either as coinfection or as superinfection of a chronic hepatitis B carrier. This dependence is the central concept of HDV biology and underlies its management.
Option A: Option A is incorrect because HDV depends on hepatitis B surface antigen, not on hepatitis C; it does not borrow hepatitis C machinery.
Option C: Option C is incorrect because HDV does not require immunosuppression; it infects immunocompetent patients who carry hepatitis B.
Option D: Option D is incorrect because CYP2E1 is relevant to acetaminophen bioactivation, not to HDV biology.
Option E: Option E is incorrect because it inverts the central concept: the defining feature of HDV is precisely that it cannot establish infection independently, since it is obligately dependent on hepatitis B surface antigen.
16. Bulevirtide is the first specifically approved agent for hepatitis D. Recall from earlier in this set that HDV depends on hepatitis B surface antigen and uses the same hepatocyte receptor as hepatitis B for cell entry. Based on that, what is bulevirtide's mechanism, and what clinical consequence follows from it?
A) It directly degrades intracellular HDV RNA, producing a rapid drop in viral load within days
B) It inhibits the NS5B polymerase shared by hepatitis D and hepatitis C, terminating RNA chain elongation
C) It replenishes hepatic glutathione, protecting hepatocytes already infected with HDV
D) It induces interferon-stimulated genes, which is why its onset of effect is immediate
E) It competitively blocks the sodium-taurocholate cotransporting polypeptide (NTCP) receptor, preventing viral entry; because it does not act inside already-infected cells, its virologic effect requires time as infected cells turn over
ANSWER: E
Rationale:
Bulevirtide is a synthetic lipopeptide derived from the preS1 domain of the hepatitis B large surface antigen that competitively blocks the sodium-taurocholate cotransporting polypeptide (NTCP), the receptor both hepatitis B and hepatitis D use to enter hepatocytes. Because it prevents new cell entry rather than acting on intracellular replication, its virologic effect develops gradually as already-infected cells turn over rather than producing an immediate viral drop.
Option A: Option A is incorrect because bulevirtide does not degrade intracellular HDV RNA; it works at the entry step, which is exactly why the effect is not immediate.
Option B: Option B is incorrect because bulevirtide is not an NS5B polymerase inhibitor and HDV is not treated with the hepatitis C polymerase inhibitors.
Option C: Option C is incorrect because glutathione repletion is the mechanism of N-acetylcysteine in acetaminophen toxicity, not bulevirtide.
Option D: Option D is incorrect because interferon-stimulated gene induction describes pegylated interferon; bulevirtide acts by entry blockade and its effect is delayed, not immediate.
17. In acetaminophen overdose, hepatotoxicity arises from a specific metabolic pathway. At therapeutic doses most acetaminophen is conjugated harmlessly, but a small fraction is oxidized to a reactive metabolite. Which sequence correctly describes how overdose produces liver injury?
A) Conjugation pathways saturate, shunting more acetaminophen through CYP2E1 to the reactive metabolite NAPQI, which depletes hepatic glutathione and then binds cellular proteins, causing hepatocyte necrosis
B) Acetaminophen is directly corrosive to hepatocyte membranes, dissolving them on contact in proportion to dose
C) Acetaminophen blocks hepatic mitochondrial DNA replication, halting all hepatocyte cell division
D) Acetaminophen is converted by reverse transcriptase into a viral-like particle that triggers immune-mediated liver injury
E) Acetaminophen competitively inhibits glutathione synthesis enzymes directly, with no reactive intermediate involved
ANSWER: A
Rationale:
In overdose, the glucuronidation and sulfation conjugation pathways saturate, so a larger fraction of acetaminophen is oxidized by CYP2E1 to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is normally detoxified by conjugation with glutathione, but in overdose it depletes hepatic glutathione and then binds covalently to cellular proteins, producing mitochondrial dysfunction, oxidative stress, and hepatocyte necrosis. This pathway is the basis for the antidote's mechanism.
Option B: Option B is incorrect because acetaminophen is not directly corrosive to membranes; injury is mediated by the reactive metabolite NAPQI.
Option C: Option C is incorrect because the mechanism is not inhibition of mitochondrial DNA replication.
Option D: Option D is incorrect because no reverse transcriptase or viral-like particle is involved; that fabricates a viral mechanism.
Option E: Option E is incorrect because the central event is generation of the reactive intermediate NAPQI with glutathione depletion, not direct enzymatic inhibition of glutathione synthesis without an intermediate.
18. Building on the previous question's mechanism, N-acetylcysteine (NAC) is the antidote for acetaminophen poisoning. What is its principal mechanism in this setting?
A) It binds NAPQI directly in the bloodstream and is excreted unchanged with the bound metabolite
B) It inhibits CYP2E1 so completely that no acetaminophen can be oxidized to NAPQI
C) It provides cysteine, the rate-limiting substrate for glutathione synthesis, replenishing glutathione so residual NAPQI can be detoxified
D) It accelerates renal excretion of intact acetaminophen before any NAPQI can form
E) It neutralizes gastric acid, preventing further acetaminophen absorption from the stomach
ANSWER: C
Rationale:
N-acetylcysteine replenishes hepatic glutathione by supplying cysteine, the rate-limiting substrate for glutathione synthesis. Restoring glutathione restores the capacity to conjugate and detoxify residual NAPQI, which is why NAC is most effective early, while NAPQI is still being generated and glutathione depletion is not yet maximal.
Option A: Option A is incorrect because NAC does not act primarily by binding NAPQI in the bloodstream for excretion; its central action is glutathione repletion within hepatocytes.
Option B: Option B is incorrect because NAC does not work by completely blocking CYP2E1-mediated oxidation.
Option D: Option D is incorrect because NAC does not act by accelerating renal excretion of intact acetaminophen.
Option E: Option E is incorrect because NAC is not an antacid and does not work by neutralizing gastric acid or blocking absorption; activated charcoal addresses absorption, by a different mechanism.
19. Given how N-acetylcysteine works (replenishing glutathione to detoxify NAPQI as it forms), what does this mechanism predict about the timing of NAC administration after an acetaminophen overdose?
A) NAC is only useful if given more than 24 hours after ingestion, once NAPQI generation has peaked
B) Timing is irrelevant because NAC reverses established hepatocyte necrosis equally well at any point
C) NAC should be withheld until liver failure is confirmed, because earlier use offers no benefit
D) NAC is most effective when given early, within about 8 to 10 hours of ingestion while NAPQI is still being generated and glutathione is not yet maximally depleted, though benefit is not entirely lost later
E) NAC must be given within 30 minutes of ingestion or it has no effect whatsoever
ANSWER: D
Rationale:
Because NAC works by replenishing glutathione so that NAPQI can be detoxified as it is generated, it is most effective when given early — within roughly 8 to 10 hours of ingestion, while NAPQI is still being produced and glutathione is not yet maximally depleted. Efficacy diminishes with delay but is not entirely lost beyond that window, so NAC is still given in late presentations.
Option A: Option A is incorrect because NAC is most useful early, not specifically after 24 hours; delay reduces benefit.
Option B: Option B is incorrect because timing matters greatly and NAC does not equally reverse established necrosis at any point.
Option C: Option C is incorrect because withholding NAC until liver failure is confirmed forfeits the early window where it is most effective; it should be started promptly when overdose is suspected.
Option E: Option E is incorrect because the effective window is on the order of hours (about 8 to 10), not a rigid 30-minute cutoff after which it is useless.
20. N-acetylcysteine is the antidote for acetaminophen toxicity, but its role has expanded. A landmark trial examined NAC in acute liver failure NOT caused by acetaminophen. What did that evidence show?
A) NAC was harmful in non-acetaminophen acute liver failure and is now contraindicated outside acetaminophen poisoning
B) Intravenous NAC improved transplant-free survival in non-acetaminophen acute liver failure, with benefit concentrated in patients with early-grade (I-II) encephalopathy and little benefit in advanced (III-IV) encephalopathy
C) NAC produced identical, large survival benefits regardless of encephalopathy grade, including in deep coma
D) NAC was effective only when combined with high-dose corticosteroids in non-acetaminophen disease
E) NAC fully reversed established cirrhosis in the majority of treated patients
ANSWER: B
Rationale:
A landmark controlled trial showed that intravenous NAC improved transplant-free survival in non-acetaminophen acute liver failure, though by a more modest margin than in acetaminophen-induced disease. The benefit was driven by patients with early-grade (I-II) encephalopathy; those with advanced (III-IV) encephalopathy did not benefit significantly, likely reflecting irreversible injury at that stage. NAC is now recommended in both acetaminophen and non-acetaminophen acute liver failure.
Option A: Option A is incorrect because NAC was beneficial, not harmful, and is not contraindicated outside acetaminophen poisoning.
Option C: Option C is incorrect because the benefit was concentrated in early-grade encephalopathy, not uniform across all grades including deep coma.
Option D: Option D is incorrect because the benefit was demonstrated for NAC itself and did not depend on combination with high-dose corticosteroids.
Option E: Option E is incorrect because NAC improves transplant-free survival; it does not reverse established cirrhosis.
21. A patient with acute liver failure is being evaluated in the intensive care unit. The team applies the King's College Criteria. What is the clinical purpose of these criteria?
A) To estimate the dose of N-acetylcysteine required based on body weight
B) To classify the grade of hepatic encephalopathy on a numeric scale
C) To determine the specific viral cause of the liver failure
D) To predict which patients will respond to corticosteroid therapy
E) To identify patients unlikely to survive without liver transplantation, prompting urgent transplant listing
ANSWER: E
Rationale:
The King's College Criteria are the most widely used prognostic tool for identifying acute liver failure patients who are unlikely to survive without liver transplantation. Meeting the criteria — which differ for acetaminophen-induced versus non-acetaminophen disease — should prompt urgent listing for emergency transplantation.
Option A: Option A is incorrect because NAC dosing is weight-based by protocol and is not derived from the King's College Criteria.
Option B: Option B is incorrect because grading encephalopathy uses separate clinical scales; the King's College Criteria incorporate encephalopathy grade as one element but their purpose is prognostic, not to grade encephalopathy.
Option C: Option C is incorrect because the criteria are prognostic, not diagnostic of viral etiology.
Option D: Option D is incorrect because the criteria do not predict corticosteroid responsiveness; they identify candidates for transplantation.
22. In acute liver failure, intensive care unit management addresses several simultaneous threats. Which statement correctly pairs a complication of acute liver failure with an appropriate first-line pharmacologic approach?
A) Cerebral edema and intracranial hypertension are leading causes of death and are addressed with osmotherapy such as mannitol or hypertonic saline; for the vasodilated, high-output shock of acute liver failure, norepinephrine is the first-line vasopressor
B) Hypertensive crisis is the leading threat, treated first-line with intravenous beta-blockade
C) The vasodilatory shock of acute liver failure is best treated first-line with high-dose dopamine, with norepinephrine avoided
D) Lactulose is firmly proven to improve survival in acute liver failure and should be dosed to aggressive catharsis
E) Stress ulcer prophylaxis is contraindicated in acute liver failure because acid suppression worsens encephalopathy
ANSWER: A
Rationale:
Cerebral edema and intracranial hypertension are leading causes of death in acute liver failure and are managed with osmotherapy — mannitol for intracranial pressure crises and hypertonic saline as prophylaxis against cerebral edema. The hemodynamic profile is a vasodilated, high-cardiac-output state, and norepinephrine is the first-line vasopressor, with vasopressin analogs added as second-line.
Option B: Option B is incorrect because hypertensive crisis is not the leading threat; the characteristic problem is vasodilatory shock, and beta-blockade is not the first-line intervention.
Option C: Option C is incorrect because norepinephrine — not high-dose dopamine — is first-line for the vasodilatory shock of acute liver failure.
Option D: Option D is incorrect because lactulose evidence in acute liver failure is limited rather than firmly proven, and excessive administration causes bowel distension that can impair surgical access; it should be titrated to a few soft stools, not catharsis.
Option E: Option E is incorrect because stress ulcer prophylaxis with proton pump inhibitors or H2 blockers is standard in acute liver failure, not contraindicated.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.